Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Equity Ratio (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Equity Ratio data on record, last reported at 1.32 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 277.72% year-over-year to 1.32; the TTM value through Sep 2025 reached 1.32, down 277.72%, while the annual FY2024 figure was 0.66, 18.17% down from the prior year.
  • Equity Ratio reached 1.32 in Q3 2025 per MBRX's latest filing, down from 0.17 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q4 2021 and bottomed at 1.32 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.68, with a median of 0.89 recorded in 2021.
  • Peak YoY movement for Equity Ratio: soared 81.82% in 2021, then tumbled 277.72% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.94 in 2021, then dropped by 3.25% to 0.91 in 2022, then decreased by 10.96% to 0.81 in 2023, then fell by 18.17% to 0.66 in 2024, then tumbled by 299.73% to 1.32 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 1.32 in Q3 2025, 0.17 in Q2 2025, and 0.66 in Q1 2025.